1834 Investment Advisors Co. Purchases 715 Shares of Edwards Lifesciences Co. (NYSE:EW)

1834 Investment Advisors Co. lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,218 shares of the medical research company’s stock after purchasing an additional 715 shares during the quarter. 1834 Investment Advisors Co.’s holdings in Edwards Lifesciences were worth $608,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in EW. Vanguard Group Inc. raised its holdings in Edwards Lifesciences by 1.1% in the first quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock worth $5,061,277,000 after buying an additional 600,994 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after acquiring an additional 809,605 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after acquiring an additional 2,390,137 shares in the last quarter. AustralianSuper Pty Ltd boosted its stake in Edwards Lifesciences by 17.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after purchasing an additional 494,604 shares during the last quarter. Finally, Champlain Investment Partners LLC increased its holdings in shares of Edwards Lifesciences by 3.1% in the 1st quarter. Champlain Investment Partners LLC now owns 2,964,168 shares of the medical research company’s stock worth $283,256,000 after purchasing an additional 88,205 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,250 shares of company stock worth $2,746,988. 1.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

EW has been the topic of several research analyst reports. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Piper Sandler dropped their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup decreased their target price on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, October 1st. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Finally, UBS Group cut their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $65.75 on Thursday. The company has a market capitalization of $39.61 billion, a price-to-earnings ratio of 9.49, a PEG ratio of 3.80 and a beta of 1.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The stock’s 50-day simple moving average is $67.75 and its 200-day simple moving average is $77.18. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the firm earned $0.59 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. As a group, analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.